Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Maria-Goeppert-Str. 1, 23562 Lübeck, Germany.
Hum Genet. 2012 Oct;131(10):1627-38. doi: 10.1007/s00439-012-1188-9. Epub 2012 Jul 1.
Biomarkers are of increasing importance for personalized medicine, with applications including diagnosis, prognosis, and selection of targeted therapies. Their use is extremely diverse, ranging from pharmacodynamics to treatment monitoring. Following a concise review of terminology, we provide examples and current applications of three broad categories of biomarkers-DNA biomarkers, DNA tumor biomarkers, and other general biomarkers. We outline clinical trial phases for identifying and validating diagnostic and prognostic biomarkers. Predictive biomarkers, more generally termed companion diagnostic tests predict treatment response in terms of efficacy and/or safety. We consider suitability of clinical trial designs for predictive biomarkers, including a detailed discussion of validation study designs, with emphasis on interpretation of study results. We specifically discuss the interpretability of treatment effects if a large set of DNA biomarker profiles is available and the number of therapies is identical to the number of different profiles.
生物标志物在个性化医疗中的重要性日益增加,其应用包括诊断、预后和靶向治疗的选择。它们的用途非常多样化,从药效学监测到治疗监测。在简要回顾术语后,我们提供了三类广泛的生物标志物——DNA 标志物、DNA 肿瘤标志物和其他一般生物标志物的示例和当前应用。我们概述了识别和验证诊断和预后生物标志物的临床试验阶段。预测生物标志物,通常称为伴随诊断测试,根据疗效和/或安全性预测治疗反应。我们考虑了预测生物标志物的临床试验设计的适用性,包括对验证研究设计的详细讨论,重点是研究结果的解释。如果有大量的 DNA 生物标志物图谱可用,并且治疗方法的数量与不同图谱的数量相同,我们将特别讨论治疗效果的可解释性。